Edward Pershing Increases Stake in Provectus Biopharmaceuticals via Note Conversions

Edward Pershing, Chairman and CEO of Provectus Biopharmaceuticals, Inc. (PVCT), filed an Amendment No. 3 to his Schedule 13D on July 22, 2026, reporting a beneficial ownership of 52,441,275 shares, representing 11.61% of the company. This filing reflects several recent transactions involving the conversion of secured convertible promissory notes into Series D-1 Convertible Preferred Stock. Between May 7 and June 5, 2026, Pershing saw approximately $220,000 in principal amount of notes automatically convert into preferred shares. His total holdings include 176,000 shares held directly, over 2.8 million shares via a retirement plan, and more than 32 million shares issuable upon the conversion of preferred stock and remaining promissory notes. Additionally, the reporting person holds 16,980,144 shares issuable upon the exercise of stock options exercisable within 60 days. Pershing also maintains shared voting power over 162,350 shares held by his spouse, a retirement plan, a grandchild's custodial account, and his non-profit foundation. The acquisitions were funded through personal resources and a personal line of credit.